Kirk Evoy, Pharm.D., BCACP, BC-ADM, CTTS, FCCP, FTSHP

Dr. Kirk Evoy smiling and wearing a suit

Clinical Associate Professor of Pharmacotherapy and Translational Sciences, UT Austin
Adjoint Associate Professor, UT Health San Antonio
Ambulatory Care Clinical Pharmacist, University Health
Fellow of Pfizer Centennial Professorship in Pharmacy

Kirk E. Evoy is a Clinical Associate Professor in the Pharmacotherapy Division of the College of Pharmacy at The University of Texas at Austin, as well as an Adjoint Associate Professor in the School of Medicine at the University of Texas Health San Antonio. In addition to his teaching and research responsibilities within the college, Dr. Evoy also cares for patients as an ambulatory pharmacist within University Health in San Antonio.

Dr. Evoy completed his Pre-pharmacy and Doctor of Pharmacy coursework at Purdue University. Upon completion of pharmacy school, he went on to complete a PGY1 Pharmacy Practice Residency at the University of Wisconsin Hospital and Clinics in Madison, Wisconsin followed by a PGY2 Ambulatory Care Residency at Saint Joseph Regional Medical Center in Mishawaka, Indiana. In addition to his residency training, Dr. Evoy completed two teaching certificate programs and a Certificate of Added Training in Global Health, and has earned Board Certification as an Ambulatory Care Pharmacist (BCACP), Advanced Diabetes Manager (BC-ADM), and Tobacco Treatment Specialist (CTTS).

Dr. Evoy’s primary areas of research include substance use disorders and smoking cessation.  His clinical focus is primary care, particularly diabetes management, smoking cessation, with additional interests in transitions of care and global health.

Dr. Evoy’s research program seeks to improve the health of patients with substance use disorders, centering around three primary foci:

1) Emerging trends in prescription drug misuse, with an emphasis on the growing misuse liability of gabapentinoids

2) Opioid overdose prevention, with an emphasis on pharmacy accessibility of naloxone and buprenorphine

3) Smoking cessation, with an emphasis on effective support of vulnerable patient populations

He is also passionate about fostering early student research opportunities, focusing much of this work on community service learning that pairs research training with projects that positively impact local community health.

Publications:

  1. Advancing Pharmacist Payment Parity Workgroup. State of the Union: A Review of State-Based Laws and Regulations Supporting Pharmacist Payment Parity and Reimbursement. (article accepted for publication in J Am Coll Clin Pharm)
  2. Green M, Vadiei N, Veltri CA, Grundmann O, Evoy KE. Kratom as a potential substance use disorder harm reduction agent. Front. Public Health 2024;12:1416689.
  3. Evoy KE. Introduction to Manuscript Development: Pearls for New Writers. (book chapter accepted for publication in ACCP Ambulatory Care Pharmacist’s Survival Guide, 5th Ed.)
  4. Evoy KE, Torres EL. Development of a Standing Delegated Order for Pharmacist-Driven Naloxone Prescribing and Dispensing in a Safety Net Health System. (book chapter accepted for publication in ACCP Ambulatory Care Pharmacist’s Survival Guide, 5th Ed.)
  5. Isch J, Evoy KE, Raber H, Bhakta. Developing an ambulatory care APPE clinical rotation. (book chapter accepted for publication in ACCP Ambulatory Care Pharmacist’s Survival Guide, 5th Ed.)
  6. Christianson-Silva P, Lee W, Meireles C, Gelfond J, Leal Vasquez L, Evoy KE. Impact of Interprofessional Nutrition Education Workshops on Pharmacy, Nurse Practitioner, and Dietetic Students. Tex J Health Syst Pharm 2024;22(1):14-19.
  7. Humpert SR, Reveles KR, Bhakta K, Torrez SB, Evoy KE. Association of gabapentinoids with opioid-related overdose in the inpatient setting: a single center retrospective case-control study. Hosp Pharm 2024;59(2):188-197. 
  8. Humpert SR, Evoy KE, Cha A, Marquez D, Sureshbabu S, Valencia J, Bhakta K. Student-led smoking cessation education and nicotine replacement therapy distribution within a substance use disorder treatment clinic. Tex J Health Syst Pharm 2023;21(1):9-13. 
  9. Loera LJ, Hill LG, Evoy KE, Reveles KR. Research and scholarly methods: Audit studies. J Am Coll Clin Pharm 2023;6(5):521-527.
  10. Evoy KE, Humpert SR, Torrez SB, Hussein H, Covvey JR. Quetiapine and olanzapine misuse prevalence in a US general population sample. Ment Health Clin 2023;13(2):25-35.
  11. Covvey JR, Blakely ML, Singh R, Peckham AM, Evoy KE. Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse. Res Social Admin Pharm 2023;19(4):599-609.
  12. Sokol M, Do A, Hui D, St. Jacques S, Sureshbabu S, Weerakoon-Wijeratne A, Bhakta K, Humpert S, Witry M, Evoy KE. Community Pharmacists’ Counseling Regarding Nicotine Replacement Therapy: A Secret Shopper Study. J Am Pharm Assoc 2023;63(2):574-581.
  13. Lai RK, Friedson KE, Reveles KR, Bhakta K, Gonzales G, Hill LG, Evoy KE. Naloxone Accessibility Without an Outside Prescription from U.S. Community Pharmacies: A Systematic Review. J Am Pharm Assoc 2022;62(6):1725-1740.
  14. Eaves AC, Teng C, Evoy KE, Frei CR. Retrospective cohort evaluating the comparative-effectiveness of ceftaroline and daptomycin as first-line therapies for inpatient treatment of diabetic foot infection in the United States Veterans Health Care System. Drugs Real World Outcomes 2022;9(4):609-615. 
  15. Evoy KE, Covvey JR, Campbell LS. Gabapentinoid Misuse. In: Irons B, Meredith A, eds. Ambulatory Care Self-Assessment Program, 2022 Book 3. Neurologic Care and Pain Management. Lenexa, KS: American College of Clinical Pharmacy, 2022:123-141. ISBN: 978-1-952291-58-6.
  16. Torres E, Evoy KE, Thomas L. Outpatient Opioid and Naloxone Prescribing Practices at an Academic Medical Center During the COVID-19 Pandemic. J. Pain Palliat. Care Pharmacother. 2022;36(3):178-186.
  17. Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel HN, Peckham AM, Chen C, Ganetsky VS, Yeung MS, Zagorski CM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend 2022;237:109518. DOI: 10.1016/j.drugalcdep.2022.109518
  18. Evoy KE, Hill LG, Davis CS. Reply to Letter to the Editor Regarding Article: “Considering the Potential Benefits of Over-The-Counter Naloxone” Integr Pharm Res Pract 2021;10:77-78. DOI: 10.2147/IPRP.S327403
  19. Desai PH, Taylor O, Shah KJ, Evoy KE, Peckham AM. Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. Ment Health Clin 2021;11(4):225-230. DOI: 10.9740/mhc.2021.07.225
  20. Evoy KE, Peckham AM, Covvey JR, Tidgewell KJ. Gabapentinoid pharmacology in the context of emerging misuse liability. J Clin Pharmacol 2021;61(S2):S89-S99. DOI: 10.1002/jcph.1833.
  21. Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM. Authors’ Reply to Bonnet et al. “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”. Drugs 2021;81(5):615-617. DOI: 10.1007/s40265-021-01495-0
  22. Ibiloye EA, Barner JC, Lawson KA, Rascati KL, Evoy KE, Peckham AM. Prevalence of and factors associated with gabapentinoid use and misuse among Texas Medicaid recipients. Clin Drug Investig 2021;41:245-253. DOI: 10.1007/s40261-021-01009-6
  23. Evoy KE, Hill LG, Davis CS. Considering the potential benefits of over-the-counter naloxone.  Integr Pharm Res Pract 2021;10:13-21. DOI: 10.2147/IPRP.S244709
  24. Evoy KE, Covvey JR, Peckham AM, Reveles KR. Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. Int J Clin Pharm 2021;43(4):1055-1064. DOI: 10.1007/s11096-020-01217-8
  25. Peckham AM, Covvey JR, Evoy KE. Letter to the Editor: Comment on “Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth”. Pain Ther 2021. ePub+ DOI: 10.1007/s40122-020-00222-z
  26. Hill LG, Loera L, Evoy KE, Renfro M, Torrez S, Zagorski C, Perez J, Jones S, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, United States. Addiction 2021;116(6):1505-1511. DOI: 10.1111/add.15314
  27. Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs 2021;81(1):125-156. DOI: 10.1007/s40265-020-01432-7
  28. Contreras J, Baus C, Brandt C, Witry M, Peters J, Evoy KE. Pharmacist Counseling When Dispensing Naloxone Via Standing Order: A Secret Shopper Study of Four Chain Pharmacies. J Am Pharm Assoc 2021;61(2):e94-e99. DOI: 10.1016/j.japh.2020.10.010
  29. Evoy KE, Roccograndi L, Le S, Leonard CE, Covvey JR, Ochs L, Peckham AM, Soprano SE, Reveles KR. National Outpatient Medication Utilization for Opioid and Alcohol Use Disorders from 2014-2016. J Subst Abuse Treat 2020;119:108141. DOI: 10.1016/j.jsat.2020.108141
  30. Covvey JR, Vogel SM, Peckham AM, Evoy KE. Prevalence and characteristics of self-reported kratom use in a representative US general population sample. J Addict Dis 2020;38(4):506-513. DOI: 10.1080/10550887.2020.1788914
  31. Evoy KE, Leonard CE, Covvey JR, Ochs L, Peckham AM, Soprano S, Reveles KR. Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States. Subst Abuse 2020;14:1-4. DOI: 10.1177/1178221819894588
  32. Hill LG, Evoy KE, Reveles KR. Reply to Letter to the Editor Regarding “Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction.” J Am Pharm Assoc. 2020;60(5):E22-23. DOI: 10.1016/j.japh.2020.02.019
  33. Moton R, Baus C, Brandt C, Coleman A, Kennedy K, Swank S, Tran M, Kazen K, Allen S, Moote R, Evoy KE. Stop the Bleed: an interprofessional community service learning project assessing the efficacy of pharmacist-led hemorrhage control education for laypersons. Disaster Med Public Health Prep 2021;15(3):271-276.  DOI: 10.1017/dmp.2020.8 
  34. Mootz ML, Britt RS, Mootz AA, Lee GC, Reveles KR, Evoy KE, Teng C, Frei CR. Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. Hosp Pract 2019;47(4):186-191. DOI: 10.1080/21548331.2019.1676540
  35. Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR. Impact of Student Pharmacist-Led Naloxone Academic Detailing at Community Pharmacies in Texas. J Am Pharm Assoc 2019;60(1):81-86. DOI: 10.1016/j.japh.2019.09.007
  36. Evoy KE, Raber H. Tobacco Use Disorder. In: Dong BJ, Elliott DP, eds. Ambulatory Care Self-Assessment Program, 2019 Book 3. Neurologic Care and Pain Management. Lenexa, KS: American College of Clinical Pharmacy, 2019:7-33. ISBN 13: 978-1-939862-93-8.
  37. Hill LG, Evoy KE, Reveles KR. Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. J Am Pharm Assoc 2019;59(6):779-782. DOI: 10.1016/j.japh.2019.06.019
  38. Evoy KE, Ford KH, Nduaguba SA, Taylor A, Thomas L. A Pilot Study Assessing the Addition of a Quit and Win Program to Pharmacist-Led Intensive Smoking Cessation Therapy in a Predominantly Underserved, Minority Population. Tob Prev Cessation 2019;5(44):1-10. DOI: 10.18332/tpc/113356
  39. Hill LG, Reveles KR, Evoy KE. State-level approaches to expanding pharmacists’ authority to dispense naloxone may impact accessibility. JAMA Intern Med 2019;179(10):1442-1443. DOI: 10.1001/jamainternmed.2019.3653
  40. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence or overdose: An analysis of the Food and Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm 2019;15(8):953-958. DOI: 10.1016/j.sapharm.2018.06.018  
  41. Evoy KE, Teng C, Encarnacion VG, Frescas B, Hakim J, Saklad S, Frei CR. Comparison of quetiapine abuse and misuse reports to the FDA Adverse Event Reporting System versus other second generation antipsychotics. Subst Abuse 2019;13:1-8. DOI: 10.1177/1178221819844205
  42. Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas. JAMA 2018;320(18):1934-1937. DOI: 10.1001/jama.2018.15892
  43. Evoy KE, Isch J, Raber H. Drugs That Affect Blood Coagulation, Fibrinolysis, and Hemostasis.      In:  Side Effects of Drugs Annual. Vol. 40.  Ray S, ed.  SEDA, United Kingdom: Elsevier; 2018. 
  44. Evoy KE, Siegrist EA, Huang Y. Gabapentinoid Abuse: An Alarming Trend. TSHP Journal 2018;17(1):6-11.
  45. Evoy KE, Yin SL. Pilot Study Regarding Pharmacist Awareness and Attitudes Regarding Gabapentinoid Abuse. TSHP Journal 2018;17(1):12-15.
  46. Peckham AM, Evoy KE, Ochs L, Covvey JR. Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern? Subst Abuse. 2018;12:1-8. DOI: 10.1177/1178221818801311 
  47. Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA. Predictors of gabapentin overuse with or without concomitant opioids in a commercially-insured US population. Pharmacotherapy 2018;38(4):436-443. DOI: 10.1002/phar.2096
  48. Whitaker A, Cosimi RA, Reveles KR, Evoy KE.  Bezlotoxumab:  A Novel Drug Approval for Reduction of Recurrent Clostridium difficile Infection.  Infect Dis Clin Pract 2018;26(2):60-65. DOI: 10.1097/IPC.0000000000000571
  49. Kitten A, Hallowell S, Saklad SR, Evoy KE.  Pimavanserin: a novel drug to treat Parkinson’s disease psychosis. Innov Clin Neurosci 2017;15(1-2):16-22. PMCID: PMC5819716
  50. Britt RS, Evoy KE, Lee GC, Reveles KR, Sorensen KM, Jones X, Bollinger M, Frei CR.  Ceftaroline fosamil use in the United States Veterans Health Care System. Drugs 2017;77(12):1345-1351. DOI: 10.1007/s40265-017-0785-2
  51. Raber H, Isch J, Evoy KE.  Drugs That Affect Blood Coagulation, Fibrinolysis, and Hemostasis.  In:  Side Effects of Drugs Annual. Vol. 39.  Ray S, ed.  SEDA, United Kingdom: Elsevier; 2017. Pages 359-372.
  52. Evoy KE, Harsh K, Langton E, Lee G, Battjes E.  Medical Resident Alumni Perspectives Regarding Preferred Pharmacotherapy Rotation Format. SM J Fam Med 2017;1(1):1004. ISSN: 2576-0262.
  53. Evoy KE, Morrison M, Saklad SR.  Abuse and Misuse of Pregabalin and Gabapentin.  Drugs 2017;77(4):403-426. DOI: 10.1007/s40265-017-0700-x
  54. Abel SR, Evoy KE.  The Eyes Have It! Update on Common Conditions Affecting the Eye. Pharmacy Tech Topics 2017;22(2):1-35.
  55. Raber H, Evoy KE, Lim L.  Anti-inflammatory and antipyretic analgesics and drugs used in gout.  In:  Side Effects of Drugs Annual. Vol. 38.  Ray S, ed.  SEDA, United Kingdom: Elsevier; 2016. Pages 77-86.
  56. Evoy KE, Wong A, Simon S.  A cautionary tale for the physician: case report and review of food dependent-exercise-induced anaphylaxis.  Gen Int Med Clin Innov 2016;1(4):56-58. DOI:10.15761/GIMCI.1000117
  57. Evoy KE, Raber H, Battjes E, Sheridan E.  Volunteering at diabetes camp: experience from the pharmacy residents' perspective. Curr Pharm Teach and Learn 2016;8(3):437-441. DOI: 10.1016/j.cptl.2016.02.018
  58. Vogeler T, McClain C, Evoy KE.  Combination bupropion SR and varenicline for smoking cessation: a systematic review.  Am J Drug Alcohol Abuse 2016;42(2):129-39. DOI: 10.3109/00952990.2015.1117480
  59. Raber H, Ali A, Dethloff A, Evoy KE, Helmen J, Lim L, Nguyen D, Sheridan E.      Anti-inflammatory and antipyretic analgesics and drugs used in gout.  In:  Side Effects of Drugs Annual. Vol. 37.  Ray S, ed.  SEDA, United Kingdom: Elsevier; 2015.  Pages 115-128.
  60. Evoy KE, Fischer J, Mably M. Development of ambulatory care pharmacist positions under financial constraints.  Am J Health Syst Pharm 2015;72(16):1350-1353. DOI: 10.2146/ajhp140501
  61. Evoy KE, Malone KM, Gonzalvo JD, Ramsey DC, Sheehan AH, Sprunger TL. Implementing mentoring into a pharmacy teaching and learning curriculum. Am J Health Syst Pharm 2015;72(11):906-909. DOI: 10.2146/ajhp140873
  62. Patel KV, Aspesi AV, Evoy KE. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Ann Pharmacother 2015;49(4):477-483. DOI: 10.1177/1060028015570467
  63. Evoy KE, Look K, Margolis A. Statistics Review Part 6: Bias in Randomized Controlled Trials.  JPSW 2014;17:19-21.
  64. Evoy KE, Weber A, North A. 2013 Pharmacy Residency Cheese Curd Crawl: a scientific approach to critiquing fine cuisine. JPSW 2014;17:5-9.
  65. Evoy KE, Abel SR. Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema. Ann Pharmacother 2013;47(6):811-8.DOI: 10.1345/aph.1S013      
  66. Evoy KE, Abel SR. Aflibercept:  newly approved for the treatment of macular edema following central retinal vein occlusion. Ann Pharmacother 2013;47(6):819-27. DOI: 10.1345/aph.1R705
  1. San Antonio Preceptor Excellence Award for Ambulatory Care, University of Texas at Austin College of Pharmacy, 2024
  2. Fellow, Texas Society of Health-System Pharmacy, 2024
  3. Awarded First Place Best Poster at the San Antonio Military Health and Universities (SURF) Conference, 2023
  4. Fellow, American College of Clinical Pharmacy, 2023
  5. Lou Cuellar Star Award, Texas Society of Health-System Pharmacists, 2023
  6. Awarded Best Quality Improvement Poster at the 2022 University of Texas at Austin Interprofessional Health Showcase in Austin, TX, 2022
  7. Awarded Third Place People's Choice Award for overall best poster at University of Texas at Austin Interprofessional Health Showcase in Austin, TX, 2022
  8. Awarded Best PharmD Poster at University of Texas at Austin Celebrating Pharmacy Research Excellence Day, 2022
  9. New Investigator Award, American College of Clinical Pharmacy, 2021
  10. Outstanding Paper of the Year Award, American College of Clinical Pharmacy for paper: Hill, et al. Addiction 2021;116(6):1505-1511., 2022
  11. Awarded Best Research Fellowship Poster at the American College of Clinical Pharmacy Annual Meeting, 2021
  12. Top Ten Faculty Recognition, University of Texas at Austin College of Pharmacy, 2021
  13. San Antonio Preceptor Excellence Award for Ambulatory Care, University of Texas at Austin College of Pharmacy, 2021
  14. Old Masters Rising Professional outstanding young alumni award, Purdue University, 2021
  15. Platinum Ribbon poster award, Academy of Managed Care Pharmacy Annual Meeting, 2021
  16. Outstanding San Antonio Faculty Mentor Award, University of Texas at Austin College of Pharmacy, 2020
  17. Pharmacy Mentor Award, Texas Society of Health-System Pharmacists, 2020
  18. Top Abstract Award, Celebrating Pharmacy Research Excellence Day, 2020
  19. Community Engagement Hero Award for Outstanding Community Researcher, Institute for Integration of Medicine and Science, 2019
  20. Faculty Mentor for student group awarded Community Engagement Hero Award for Outstanding Community Health Improvement Project, Institute for Integration of Medicine and Science, 2019
  21. Outstanding Paper of the Year Award, American College of Clinical Pharmacy Ambulatory Care PRN for paper: Evoy, et al. JAMA 2018;320(18):1934-1937, 2019
  22. Preceptor Excellence Award for Interprofessional Education, University of Texas at Austin College of Pharmacy, 2019
  23. Purdue University College of Pharmacy Outstanding Early Career Award Recipient, 2019
  24. Judges Choice Award for Top Poster, University of Texas Health San Antonio Community Service Learning Conference, 2019
  25. Blue Ribbon Award as a Top 3 Abstract, University of Texas Health San Antonio Community Service Learning Conference, 2019
  26. American Society of Health-System Pharmacists Foundation Drug Therapy Research Award Recipient, 2018
  27. San Antonio Preceptor of the Year, The University of Texas at Austin College of Pharmacy, 2017-2018
  28. Selected as Walmart Scholar Faculty Mentor, 2018
  29. Phi Lamda Sigma Pharmacy Leadership Society Inductee, 2017
  30. Judges Choice Award Top Poster, Texas Society of Health-System Pharmacists Annual Seminar, 2018
  31. Judges Choice Award Top Poster, University of Texas Health San Antonio Community Service Learning Conference, 2018
  32. San Antonio Preceptor Excellence Award for Ambulatory Care, The University of Texas at Austin College of Pharmacy, 2016-2017
  33. Outstanding San Antonio Faculty Mentor Award, The University of Texas at Austin College of Pharmacy, 2015-2016
  34. Nicholas G. Popovich IPTeC Teaching Award, Indiana Pharmacy Teaching Certificate Program, 2015
  35. Rho Chi Pharmacy Honors Fraternity Inductee, 2011
Contact Information
Phone:
210-567-8304
Fax number:
210-567-8328
UT Health Science Center San Antonio
Pharmacotherapy Education and Research Center
7703 Floyd Curl Drive – MC 6220
San Antonio TX 78229